Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Ranibizumab "Treat and Extend" in Diabetic Macular Edma (OPTIMAL)

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: February 15, 2011
Last updated: February 20, 2017
Last verified: February 2017

February 15, 2011
February 20, 2017
January 2011
November 2012   (Final data collection date for primary outcome measure)
Change in Best Corrected Visual Acuity(BCVA) [ Time Frame: from month 0 (baseline) to month 12 ]
Same as current
Complete list of historical versions of study NCT01297569 on Archive Site
  • change in central retinal thickness (CRT) [ Time Frame: from month 0 to month 12 ]
  • the number of injections needed [ Time Frame: 12 months ]
  • the number of patients with improvement in BCVA from baseline [ Time Frame: 12 months ]
  • the number of patients with > 5, 10 and 15 letters improvement from baseline, the latter including patients reaching BCVA >84 [ Time Frame: 12 months ]
Same as current
Not Provided
Not Provided
Ranibizumab "Treat and Extend" in Diabetic Macular Edma
An Open-label, Prospective, Multicentre, Uncontrolled, Proof of Concept Study Assessing the Efficacy of Lucentis (Ranibizumab) Administered by an Individualized "Treat and Extend" Dosing Regimen in Patients With Visual Impairment Due to Diabetic Macular Edema
This study is designed to explore a more individualized treatment regime based on achievement of disease stability to define a personal optimal treatment interval with ranibizumab in patients with visual impairment due to diabetic macular edema.
Not Provided
Phase 4
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Diabetic Macular Edema
Drug: Ranibizumab
Experimental: Ranibizumab
Intervention: Drug: Ranibizumab
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
November 2012
November 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Visual impairment due to focal or diffuse macular edema with center involvement
  • Diabetes type 1 or 2, HbA1c < 12.0%
  • CRT = or > 250 μm

Exclusion Criteria:

  • Active inflammation or infection
  • Uncontrolled glaucoma
  • Iris neovascularization, active proliferative retinopathy or vitreomacular traction
  • Prior laser photocoagulation according to defined timelines
  • History of stroke, uncontrolled hypertension

Other protocol-defined inclusion/exclusion criteria may apply

Sexes Eligible for Study: All
18 Years to 18 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
2010-021182-76 ( EudraCT Number )
Not Provided
Not Provided
Not Provided
Not Provided
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP